SHSvasti Haricharan

Svasti Haricharan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Svasti Haricharan has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient Sociodemographic Factors Impact the Breast Cancer Microenvironment

    by Jerry T. DeWitt, Daisy Jimenez-Tovar, Elena Oropeza, Esra Tiftik Karabay, Casandra Nguyen, Astha Lamichhane, Megha Raghunathan, Blake Gabel, Badri Narayanan. Narasimhan, Fenna Candy, et al.

    Hormone receptor positive (HR+) breast cancer is the most common breast cancer subtype globally and remains a leading cause of cancer-related death in women. Black women diagnosed HR+ breast cancer experience significantly worse outcomes than White women, a disparity that persists even after accounting for factors such as healthcare access and educational attainment. Understanding the biological mechanisms underlying these differences has been limited by the underrepresentation of Black patients in genomic datasets. To address this gap, we generated an HR+ breast cancer transcriptomic dataset enriched for Black patients while controlling for access to healthcare and education level. Tumors from Black women showed enrichment of tumor microenvironment-related signatures, including increased collagen deposition and prognostically unfavorable T-cell landscapes. Data from in vitro and in vivo experimental models showed that race-aligned collagen deposition patterns were driven, at least in part, by tumor cell-intrinsic signaling and promoted metastatic phenotypes associated with poorer outcomes. Further analysis of the patient transcriptomic dataset revealed that unfavorable T-cell signatures previously attributed to race or ancestry were more strongly associated with poverty burden. Across multiple independent datasets, STAT4 emerged as a potential master regulator of this poverty-associated immune phenotype. Collectively, these findings suggest that molecular features of breast tumors are shaped by both biological and structural factors linked to self-identified race and socioeconomic disadvantage. These results demonstrate that integrating social determinants of health with molecular analyses can reveal mechanisms contributing to cancer outcome disparities and provide a foundation for the development of more effective and equitable precision oncology approaches.

  • Open Access

    Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence

    by Aloran Mazumder, Jerry Dewitt, Elena Oropeza, Nindo Punturi, Daniel Lozano, Megha Raghunathan, Jonathan Piscitelli, Elham Sajjadi, Elena GueriniRocco, Konstantinos Venetis, et al.

    Estrogen receptor-positive breast cancer remains a leading cause of cancer-related death in women, with mortality largely driven by late recurrence of treatment-resistant disease. Loss of MLH1 promotes resistance to estrogen-targeting therapies by uncoupling cell cycle progression from estrogen regulation. Here, we show that even when MLH1 is abundantly expressed, aberrant cytoplasmic localization in a subset of tumor cells drives endocrine therapy resistance by enabling estrogen-independent growth. This resistance arises from failure to undergo robust cell cycle arrest in response to endocrine therapy, creating acute dependency on CDK4/6 activity. Consequently, CDK4/6 inhibitors induce strong regression in cells with cytoplasmic MLH1 compared to cells with nuclear MLH1. As cytoplasmic localization occurs in ~11% of ER+ patients, it represents a contributor to MLH1 dysregulation. Incorporating cytoplasmic MLH1 localization into diagnostics could guide the use of CDK4/6 inhibitors in this hard-to-treat subset.

  • Open Access

    The impact of patient biology on racial disparities in breast cancer outcome

    by JT DeWitt, D Jimenez-Tovar, C Nguyen, E Oropeza, M Raghunathan, Et Karabay, A Lamichhane, E Kirk, Sa Raghavan, P Katira, et al.

    Hormone receptor positive (HR+) breast cancer is the most common subtype of breast cancer diagnosed globally. Despite effective targeted therapies, HR+ breast cancer remains a leading cause of cancer-related death in women. Long-standing epidemiological research identifies significantly worse outcomes for Black women diagnosed with HR+ breast cancer relative to White women. While structural factors such as access to healthcare and education level contribute to this outcome disparity, it persists even in analyses where these factors are controlled. In-depth analyses of the somatic molecular biology that may underlie these outcome disparities are hampered by a lack of datasets that represent Black patient populations. Here, we generate a HR+ breast cancer patient transcriptomic dataset that overrepresents Black women and controls for access to healthcare and education level. We find that signatures relating to the tumor microenvironment, i.e. collagen deposition and prognostically unfavorable T-cell landscapes are enriched in HR+ tumors from Black women. Importantly, we find, using experimental model systems in vitro and in vivo , that race-aligned collagen deposition patterns are at least partially attributable to tumor cell-intrinsic signaling and critical for Black breast cancer metastasis. We also find that unfavorable T-cell signatures in HR+ tumors from Black women, which have previously been attributed to race and ancestry, are more strongly poverty-aligned. Using multiple independent datasets, we identify STAT4 as a potential master regulator of this poverty-associated tumor immune signature. Together, these findings provide new evidence that somatic molecular biology of breast cancer patients can be modified by multiple structural factors such as self-identified race and poverty burden to promote poor patient outcomes. Integrating an understanding of structural factors into molecular cancer research is critical for implementing truly personalized, and maximally effective, oncology systems.


  • Open Access

    Advances in diagnostic and therapeutic applications of mismatch repair loss in cancer

    by JT DeWitt, D. Jimenez-Tovar, A. Mazumder, S. Haricharan


  • Open Access

    Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology

    by Jerry Tyler DeWitt, Megha Raghunathan, Svasti Haricharan


  • Open Access

    Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness

    by Elena Oropeza, Sinem Seker, Sabrina Carrel, Aloran Mazumder, Daniel Lozano, Athena Jimenez, Sabrina N. VandenHeuvel, Dillon A. Noltensmeyer, Nindo B. Punturi, Jonathan T. Lei, et al.

    Cell cycle dysregulation is prerequisite for cancer formation. However, it is unknown whether the mode of dysregulation affects disease characteristics. Here, we conduct comprehensive analyses of cell cycle checkpoint dysregulation using patient data and experimental investigations. We find that ATM mutation predisposes the diagnosis of primary estrogen receptor (ER) + /human epidermal growth factor (HER)2 − cancer in older women. Conversely, CHK2 dysregulation induces formation of metastatic, premenopausal ER + /HER2 − breast cancer ( P = 0.001) that is treatment-resistant (HR = 6.15, P = 0.01). Lastly, while mutations in ATR alone are rare, ATR / TP53 co-mutation is 12-fold enriched over expected in ER + /HER2 − disease ( P = 0.002) and associates with metastatic progression (HR = 2.01, P = 0.006). Concordantly, ATR dysregulation induces metastatic phenotypes in TP53 mutant, not wild-type, cells. Overall, we identify mode of cell cycle dysregulation as a distinct event that determines subtype, metastatic potential, and treatment responsiveness, providing rationale for reconsidering diagnostic classification through the lens of the mode of cell cycle dysregulation. .


  • Open Access

    Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

    by Svasti Haricharan, Nindo Punturi, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Jacob Schmelz, Cheryl Schmidt, Jonathan T. Lei, Vera Suman, Kelly Hunt, et al.

  • Open Access

    Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

    by Leann A. Lovejoy, Craig D. Shriver, Svasti Haricharan, Rachel E. Ellsworth

    Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.


  • Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations

    by Angelique Richardson, Burcu Darst, Genevieve Wojcik, Nikhil Wagle, Svasti Haricharan

    Despite much vaunted progress in cancer therapeutics and diagnostics, outcomes for many groups of non-White patients with cancer remain worse than those for their White compatriots. One reason for this is the lack of inclusion and representation of non-White patients in clinical trials, preclinical datasets, and among researchers, a shortfall that is gaining wide recognition within the cancer research community and the lay public. Several reviews and editorials have commented on the negative impacts of the status quo on progress in cancer research toward medical breakthroughs that help all communities and not just White patients with cancer. In this perspective, we describe the existence of research silos focused either on the impact of socioeconomic factors proceeding from systemic racism on cancer outcomes, or on genetic ancestry as it affects the molecular biology of cancer developing in specific patient populations. While both these research areas are critical for progress toward precision medicine equity, breaking down these silos will help us gain an integrated understanding of how race and racism impact cancer development, progression, and patient outcomes. Bringing this comprehensive approach to cancer disparities research will undoubtedly improve our overall understanding of how stress and environmental factors affect the molecular biology of cancer, which will lead to the development of new diagnostics and therapeutics that are applicable across cancer patient demographics.


  • Open Access

    Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome

    by Matthew N Bainbridge, Aloran Mazumder, Daisuke Ogasawara, Rami Abou Jamra, Geneviève Bernard, Enrico Bertini, Lydie Burglen, Heidi Cope, Ali Crawford, Alexa Derksen, et al.

    The endocannabinoid system is a highly conserved and ubiquitous signalling pathway with broad-ranging effects. Despite critical pathway functions, gene variants have not previously been conclusively linked to human disease. We identified nine children from eight families with heterozygous, de novo truncating variants in the last exon of DAGLA with a neuro-ocular phenotype characterized by developmental delay, ataxia and complex oculomotor abnormality. All children displayed paroxysms of nystagmus or eye deviation accompanied by compensatory head posture and worsened incoordination most frequently after waking. RNA sequencing showed clear expression of the truncated transcript and no differences were found between mutant and wild-type DAGLA activity. Immunofluorescence staining of patient-derived fibroblasts and HEK cells expressing the mutant protein showed distinct perinuclear aggregation not detected in control samples. This report establishes truncating variants in the last DAGLA exon as the cause of a unique paediatric syndrome. Because enzymatic activity was preserved, the observed mislocalization of the truncated protein may account for the observed phenotype. Potential mechanisms include DAGLA haploinsufficiency at the plasma membrane or dominant negative effect. To our knowledge, this is the first report directly linking an endocannabinoid system component with human genetic disease and sets the stage for potential future therapeutic avenues.